In this cohort study, decreasing opioid dose was associated with reduced risk of opioid use disorder and continued opioid therapy but increased risk of disenrollment compared with stable dosing, whereas the high-dose increasing trajectory was associated with an increased risk […]
PROP presents at UN Commission on Narcotic Drugs policy
PROP recently presented at the United Nations Commission on Narcotic Drugs policy meeting in Vienna, Austria. The Commission on Narcotic Drugs (CND) was established by Economic and Social Council (ECOSOC) resolution 9(I) in 1946, to assist the ECOSOC in supervising the application […]
Understanding the Risks of Long-Term Opioid Therapy for Chronic Pain
PROP members Mark Sullivan and Jane Ballantyne published this editorial in the American Journal of Psychiatry, rebutting and questioning the findings of Hasin et al. This article argues that the “opioid-adjusted” and “pain-adjusted” versions of the DSM-5 Opioid Use Disorder […]
Opioids @ Work: Hidden Scourge Sapping the Economy
In addition to untold years of productivity lost from fatal overdoses, the nation’s labor participation rate has shrunk steadily since 2000. Precise correlation is elusive, but any graph of that decline would stand in sharp contrast to the rise of […]
Increases in Disparities in US Drug Overdose Deaths by Race and Ethnicity
A Viewpoint article published in JAMA discusses the implications and takeaways from the recent CDC report on drug overdose deaths. the authors note that “Raising awareness about worsening disparities in overdose deaths among racial and ethnic minority populations and inequities […]
Is Chronic Pain a Disease?
PROP’s Jane Ballantyne and Mark Sullivan have a new paper in Journal of Pain: “Is Chronic Pain a Disease?” that argues there are many iatrogenic harms of declaring chronic pain to be a disease.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »